Serabelisib
- Generic Name
- Serabelisib
- Drug Type
- Small Molecule
- Chemical Formula
- C19H17N5O3
- CAS Number
- 1268454-23-4
- Unique Ingredient Identifier
- 43J9Q56T3W
- Background
Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).
Faeth Therapeutics Advances Novel Three-Pronged Approach for Metabolism-Driven Cancers with Promising Preclinical Results
• Faeth Therapeutics has published preclinical proof-of-concept data in the British Journal of Cancer supporting their multi-node PIKTOR approach, which combines dual PI3K/AKT/mTOR pathway inhibitors with an insulin-suppressing diet.
• The company's strategy targets cancer metabolism through simultaneous inhibition of multiple pathway nodes, showing tumor regression in endometrial and breast cancer models while potentially overcoming common resistance mechanisms.
• A Phase 2 trial in collaboration with The GOG Foundation is currently underway for patients with endometrial cancer, building on earlier clinical data that demonstrated an 80% objective response rate with the drug combination.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath